Sign In
Buy SAGE
$8.68
+0 (+0%)
At Close: Oct 30, 2025
NEW YORK, NY / ACCESSWIRE / May 4, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Sage Therapeutics, Inc. ("Sage Therapeutics") (NASDAQ:SAGE) concerning possible
NEW YORK, NY / ACCESSWIRE / May 4, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Sage Therapeutics, Inc. ("Sage Therapeutics") (NASDAQ:SAGE) concerning possible
Sage Therapeutics, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - SAGE
04:45pm, Thursday, 02'nd May 2024
NEW YORK, NY / ACCESSWIRE / May 2, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Sage Therapeutics, Inc. ("Sage Therapeutics") (NASDAQ:SAGE) concerning possible
ATTENTION Sage Therapeutics, Inc. Investors: You May Have Been Affected by Fraud - Contact Levi & Korsinsky to Discuss Your Rights
04:45pm, Thursday, 02'nd May 2024
NEW YORK, NY / ACCESSWIRE / May 2, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Sage Therapeutics, Inc. ("Sage Therapeutics") (NASDAQ:SAGE) concerning possible
An Investigation Has Commenced on Behalf of Sage Therapeutics, Inc. Shareholders. Contact Levi & Korsinsky to Discuss your SAGE Losses.
10:00am, Thursday, 02'nd May 2024
NEW YORK, NY / ACCESSWIRE / May 2, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Sage Therapeutics, Inc. ("Sage Therapeutics") (NASDAQ:SAGE) concerning possible
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Sage Therapeutics, Inc. - SAGE
09:00am, Sunday, 28'th Apr 2024
NEW YORK , April 28, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sage Therapeutics, Inc. ("Sage" or the "Company") (NASDAQ: SAGE). Such investors are advised t
Sage Therapeutics (SAGE) Q1 Earnings Miss, Sales Beat Estimates
12:31pm, Friday, 26'th Apr 2024
Sage Therapeutics' (SAGE) first-quarter 2024 results are mixed as earnings miss estimates, but sales beat the mark. The newly-launched depression drug Zurzuvae drives the company's top line.
LOS ANGELES, CA / ACCESSWIRE / April 25, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sage Therapeutic
Sage Therapeutics, Inc. (SAGE) Q1 2024 Earnings Call Transcript
02:17pm, Thursday, 25'th Apr 2024
Sage Therapeutics, Inc. (NASDAQ:SAGE ) Q1 2024 Earnings Conference Call April 25, 2024 8:00 AM ET Company Participants Ashley Kaplowitz - Vice President-Investor Relations & Capital Markets Barry Gree
Sage Therapeutics, Inc. (SAGE) Reports Q1 Loss, Tops Revenue Estimates
08:35am, Thursday, 25'th Apr 2024
Sage Therapeutics, Inc. (SAGE) came out with a quarterly loss of $1.80 per share versus the Zacks Consensus Estimate of a loss of $1.63. This compares to loss of $2.46 per share a year ago.
Sage (SAGE) Down 20% on Parkinson's Study Missing Primary Goal
12:41pm, Thursday, 18'th Apr 2024
Data from a mid-stage study show that Sage's (SAGE) experimental oral drug failed to show a statistically significant difference in treating patients with Parkinson's disease compared with a placebo.
2 Well-Priced Stocks Staging Big Swings Today
03:11pm, Wednesday, 17'th Apr 2024
Depending on who you ask, a recession is either right around the corner or the stock market is ready to rattle off a seismic bull run.
Sage Therapeutics' stock plunges as Parkinson's drug trial disappoints
09:42am, Wednesday, 17'th Apr 2024
Sage Therapeutics Inc. shares dropped 17% early Wednesday after the company said its experimental treatment for mild cognitive impairment in patients with Parkinson's disease fell flat in a clinical t
Sage Therapeutics scraps Parkinson's drug development after treatment fails mid-stage study
07:32am, Wednesday, 17'th Apr 2024
Sage Therapeutics said on Wednesday it will stop development of its experimental drug to treat Parkinson's disease after it failed a mid-stage study, sending the company's shares down 4% before the be
Sage Therapeutics to Report First Quarter 2024 Financial Results on Thursday, April 25, 2024
06:30am, Thursday, 11'th Apr 2024
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today announced that it will host a l
